Susan Desmond-Hellmann has been named to the board of directors of Affymetrix, the company said this week. Desmond-Hellman oversees regulatory affairs, medical affairs, product development, and other functions for Genentech. She also serves on the Biotechnology Industry Organization’s board of directors’ executive committee. In connection with the appointment, Desmond-Hellman received options to purchase 20,000 Affymetrix shares at a price of $32.62. The options are exercisable and expire on Nov. 17, 2014.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.